While anti-TB therapy can resolve some autoantibodies, it may also induce the formation of new autoantibodies, as observed with anti-lactoferrin and anti-myeloperoxidase (MPO) normalization, and the de novo formation of anti-PR3 and MPO antibodies [17]. This evidence concerns the gene PRTN3 and tuberculosis.